Grant awarded towards eye disease research

Article

Fight for Sight, a charity funding the research for the treatment of blindness and eye disease, has contributed grants totalling £697 350 to 7 recipients

Fight for Sight, a charity funding the research for the treatment of blindness and eye disease, has contributed grants totalling £697 350 to 7 recipients.

Research into treatments for age-related macular degeneration (AMD), glaucoma, diabetic eye disease, amblyopia, congenital cataract and keratoconus will all be provided with grants from Fight for Sight.

One of the PhD studentships has been awarded to the University of the City of London Institute of Ophthalmology and the London School of Hygiene and Tropical Medicine have received £100 000 from the charity to help them in researching the prevention of sight loss caused by trachoma. The research will study the process that causes scarring of the eyelids and gain a better understanding of trachoma.

Dr Dolores Conroy, Fight for Sight Research Officer, said: "Through these grants we are helping researchers to find ways of preventing and treating a number of serious eye conditions. We are also helping to support a new generation of vision scientists."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.